Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MILOPHENE vs CLOMIPHENE CITRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MILOPHENE is a selective estrogen receptor modulator (SERM) that acts as an antagonist in breast tissue and agonist in bone and cardiovascular tissues. It binds competitively to estrogen receptors, inhibiting estrogen-mediated proliferation in breast cancer cells.
Selective estrogen receptor modulator; competes with estrogen for binding at estrogen receptors in the hypothalamus, inhibiting negative feedback and increasing gonadotropin-releasing hormone (Gn RH) secretion, leading to increased LH and FSH release from the pituitary.
Treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors,Reduction in incidence of invasive breast cancer in women at high risk (FDA-approved),Off-label: ovulation induction in anovulatory infertility
Treatment of ovulatory dysfunction in women desiring pregnancy,Off-label: male infertility (oligospermia), induction of ovulation in assisted reproductive technology
1-2 mg/kg intravenously every 4 hours, not to exceed 100 mg per dose.
50 mg orally once daily for 5 days, starting on day 5 of menstrual cycle; may increase to 100 mg orally once daily for 5 days if ovulation not achieved.
Terminal elimination half-life is 18-24 hours, supporting once-daily dosing; prolonged in renal impairment.
Terminal elimination half-life is approximately 5–7 days (120–168 hours) for the active zu-isomer, with a longer half-life for its metabolites. This prolonged half-life leads to accumulation with repeated dosing and sustained clinical effects.
Metabolized primarily by CYP3A4 and CYP2D6 to active metabolites (e.g., N-desmethylmilophene, 4-hydroxymilophene). Undergoes enterohepatic recirculation.
Hepatic metabolism; excreted in feces; active metabolites (possibly enterohepatic recirculation).
Primarily renal excretion of unchanged drug (70-80%), with 10-15% as glucuronide conjugate; biliary/fecal elimination accounts for <10%.
Primarily fecal (approximately 50%), with about 8% renal excretion of unchanged drug and metabolites. Biliary excretion is significant, with enterohepatic recirculation contributing to prolonged elimination.
92-96% bound to albumin.
Approximately 80–90% bound to albumin, with significant binding to other plasma proteins including sex hormone-binding globulin (SHBG).
0.3-0.4 L/kg, indicating distribution primarily in extracellular fluid.
Apparent volume of distribution is large, approximately 50–100 L/kg, indicating extensive tissue distribution and accumulation, particularly in the liver and reproductive organs.
Oral: 65-75% with significant first-pass metabolism.
Oral: ~100% absorbed, but bioavailability is difficult to quantify due to extensive first-pass metabolism and enterohepatic cycling; essentially complete systemic exposure after oral administration.
GFR 30-50 m L/min: 75% of normal dose every 6 hours; GFR 15-29 m L/min: 50% of normal dose every 8 hours; GFR <15 m L/min: 25% of normal dose every 12 hours.
No specific dose adjustment guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 50% of normal dose every 6 hours; Child-Pugh Class C: contraindicated.
Contraindicated in patients with liver disease or hepatic dysfunction; no Child-Pugh based adjustments available.
Children 1 month to 12 years: 0.5-1 mg/kg intravenously every 4-6 hours, maximum 50 mg per dose; infants <1 month: 0.25-0.5 mg/kg every 6-8 hours.
Not recommended for use in children; safety and efficacy not established.
Start at 50% of adult dose, increase based on tolerance and renal function; monitor for neurotoxicity and QT prolongation.
Not indicated for use in elderly patients; no specific dosing recommendations.
Boxed Warning: Increased risk of thromboembolic events (deep vein thrombosis, pulmonary embolism) and stroke. Use with caution in patients with history of thromboembolic disorders.
Should not be used in patients with liver disease or abnormal uterine bleeding of undetermined origin.
Warnings: Thromboembolic events, stroke, endometrial hyperplasia/carcinoma, ovarian cysts, visual disturbances (e.g., cataracts, retinopathy), hepatic impairment, hypercalcemia in bone metastases. Monitor lipid profiles and liver function.
Ovarian enlargement/cysts; visual disturbances; multiple pregnancy; ovarian hyperstimulation syndrome; vasomotor symptoms; blurred vision; prolonged use may increase risk of borderline or invasive ovarian tumors.
Contraindications: Hypersensitivity to milophene or any component; pregnancy (Category X); history of thromboembolic disease (e.g., DVT, PE); undiagnosed abnormal genital bleeding; hepatic impairment (severe); concurrent use of anticoagulants.
Pregnancy; liver disease or history; abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement due to polycystic ovary syndrome; hypersensitivity to clomiphene.
Grapefruit juice may increase clomiphene levels; avoid concurrent consumption. No specific food restrictions, but maintain a balanced diet. Limit caffeine intake as it may affect fertility.
No significant food interactions. Avoid excessive alcohol consumption as it may impair fertility.
MILOPHENE is a dopamine agonist used for hyperprolactinemia. In the first trimester, there is limited human data but no evidence of increased major malformations. Risk cannot be completely excluded. In the second and third trimesters, continued use may be justified if needed. Limited studies suggest no significant increase in adverse fetal outcomes. However, dopamine agonists have been associated with fetal harm in animal studies, so cautious use is warranted throughout pregnancy.
FDA Pregnancy Category X. Clomiphene citrate is contraindicated in pregnancy. First trimester exposure associated with neural tube defects, cleft palate, and syndactyly. Second and third trimester: no data due to contraindication. Risk of multiple gestation (5-12%) increases risks of preterm labor, low birth weight, and congenital anomalies.
MILOPHENE is excreted into human breast milk. The M/P ratio is unknown but assumed to be low based on molecular weight and protein binding. Due to potential adverse effects on the infant (e.g., dopamine receptor blockade), breastfeeding is not recommended during therapy. Alternative treatments or cessation of breastfeeding should be considered.
Excreted into breast milk; M/P ratio unknown. Clomiphene may reduce milk production due to anti-estrogenic effects. Because of potential for adverse reactions in nursing infants, women are advised not to breastfeed during treatment.
Pharmacokinetic changes during pregnancy (e.g., increased plasma volume, renal clearance) may require dose adjustment. However, data are limited. Clinical monitoring of prolactin levels and symptom control is recommended. Dose may need to be increased to maintain efficacy, but the lowest effective dose should be used. No specific dose adjustment guidelines exist; therefore, individualized titration based on response is prudent.
No dose adjustments in pregnancy as drug is contraindicated. If pregnancy occurs, discontinue immediately. No pharmacokinetic studies in pregnant women; drug should not be used.
Milophene (clomiphene citrate) is a selective estrogen receptor modulator used for ovulation induction. Monitor for ovarian hyperstimulation syndrome (OHSS) with pelvic ultrasound. Limit course duration to 6 cycles due to increased risk of ovarian cancer. Use with caution in patients with liver disease or abnormal uterine bleeding. Administer on days 3-7 of menstrual cycle for optimal response.
Monitor ovarian size and estradiol levels to reduce risk of ovarian hyperstimulation syndrome (OHSS). Use only in patients with ovulatory dysfunction; rule out pregnancy before each cycle. Limit to 6 treatment cycles due to increased risk of ovarian cancer with prolonged use.
Take exactly as prescribed, typically one tablet daily for 5 days starting on cycle day 3, 4, or 5.,Notify your doctor immediately if you experience severe pelvic pain, nausea, vomiting, or sudden weight gain (signs of OHSS).,Avoid pregnancy before starting treatment; use barrier contraception until instructed.,Multiple births (especially twins) occur in about 10% of pregnancies; discuss this risk.,Report any visual disturbances (blurring, spots, flashes) promptly; discontinue use if they occur.,Do not exceed 6 treatment cycles; prolonged use increases ovarian cancer risk.
Take clomiphene citrate exactly as prescribed, typically for 5 days starting on day 3-5 of menstrual cycle.,Ovulation usually occurs 5-10 days after the last dose; have intercourse every other day during this window.,Common side effects include hot flashes, mood swings, and visual disturbances; report persistent visual changes immediately.,Risk of multiple pregnancy (mainly twins) is increased; discuss with healthcare provider.,Avoid use if pregnant, have liver disease, or have abnormal vaginal bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MILOPHENE vs CLOMIPHENE CITRATE, answered by our medical review team.
MILOPHENE is a Selective Estrogen Receptor Modulator that works by MILOPHENE is a selective estrogen receptor modulator (SERM) that acts as an antagonist in breast tissue and agonist in bone and cardiovascular tissues. It binds competitively to estrogen receptors, inhibiting estrogen-mediated proliferation in breast cancer cells.. CLOMIPHENE CITRATE is a Selective Estrogen Receptor Modulator (SERM) that works by Selective estrogen receptor modulator; competes with estrogen for binding at estrogen receptors in the hypothalamus, inhibiting negative feedback and increasing gonadotropin-releasing hormone (Gn RH) secretion, leading to increased LH and FSH release from the pituitary.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MILOPHENE and CLOMIPHENE CITRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MILOPHENE is: 1-2 mg/kg intravenously every 4 hours, not to exceed 100 mg per dose.. The standard adult dose of CLOMIPHENE CITRATE is: 50 mg orally once daily for 5 days, starting on day 5 of menstrual cycle; may increase to 100 mg orally once daily for 5 days if ovulation not achieved.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MILOPHENE and CLOMIPHENE CITRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MILOPHENE is classified as Category C. MILOPHENE is a dopamine agonist used for hyperprolactinemia. In the first trimester, there is limited human data but no evidence of increased major malformations. Risk cannot be co. CLOMIPHENE CITRATE is classified as Category A/B. FDA Pregnancy Category X. Clomiphene citrate is contraindicated in pregnancy. First trimester exposure associated with neural tube defects, cleft palate, and syndactyly. Second and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.